The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease
- 105 Downloads
Acute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established.
Two medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included 48 advanced non-small cell lung cancer patients with ILD treated with ICIs at nine institutions between January 2016 and September 2018. Variables were compared between AE-positive and -negative groups. Candidate variables were analyzed by multivariate logistic regression. A P value < 0.05 was considered statistically significant.
Anticancer treatment-related AE of ILD occurred in 12 patients (11.4%) in the chemotherapy cohort and seven patients (14.5%) in the ICI cohort. In the multivariate logistic regression analysis, ground-glass attenuation (GGA) score was the only factor significantly associated with the development of AE of ILD in both cohorts (P = 0.037 and 0.01 in the chemotherapy and ICI cohorts, respectively).
Evaluation of GGA may help predict anticancer treatment-related AE of ILD.
KeywordsAcute exacerbation Chemotherapy HRCT score Interstitial pneumonia Immune checkpoint inhibitor
The authors would like to thank Y Sakakibara, Y Wakai, Y Watanabe, T Tsutsui, T Yagi, S Yamashita, and M Doi for cooperation in collecting data. We also thank T Mitsumura and R Sakakibara for useful comments and suggestions.
Compliance with ethical standards
Conflict of interest
Yasunari Miyazaki received lecture fees from Nippon Boehringer Ingelheim Co., Ltd.
- 9.Chen YJ, Chen LX, Han MX et al (2015) The efficacy and safety of chemotherapy in patients with nonsmall cell lung cancer and interstitial lung disease: a prisma-compliant bayesian meta-analysis and systematic review. Medicine (Baltimore) 94(36):e1451. https://doi.org/10.1097/MD.0000000000001451 CrossRefGoogle Scholar
- 10.Ott PA, Bang YJ, Piha-Paul SA et al (2019) T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318–327. https://doi.org/10.1200/jco.2018.78.2276 CrossRefPubMedGoogle Scholar
- 11.Yamaguchi T, Shimizu J, Hasegawa T et al (2018) Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 125:212–217. https://doi.org/10.1016/j.lungcan.2018.10.001 CrossRefPubMedGoogle Scholar
- 12.Shibaki R, Murakami S, Matsumoto Y et al (2019) Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical Oncol (Northwood, Lond, Engl) 36(6):49. https://doi.org/10.1007/s12032-019-1274-0 CrossRefGoogle Scholar
- 15.Masuda T, Hirano C, Horimasu Y et al (2018) The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 81(1):131–139. https://doi.org/10.1007/s00280-017-3476-5 CrossRefPubMedGoogle Scholar
- 17.Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260. https://doi.org/10.1097/jto.0000000000000630 CrossRefPubMedGoogle Scholar
- 19.Kazerooni EA, Martinez FJ, Flint A et al (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 169(4):977–983. https://doi.org/10.2214/ajr.169.4.9308447 CrossRefPubMedGoogle Scholar
- 21.Suzuki H, Sekine Y, Yoshida S et al (2011) Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 41(7):914–921. https://doi.org/10.1007/s00595-010-4384-z CrossRefPubMedGoogle Scholar
- 27.Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537–546. https://doi.org/10.1200/jco.18.00149 CrossRefPubMedGoogle Scholar
- 28.Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062. https://doi.org/10.1200/jco.2011.39.5848 CrossRefPubMedGoogle Scholar
- 30.Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933. https://doi.org/10.1200/jco.2017.74.3062 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Isobe K, Kaburaki K, Kobayashi H et al (2018) New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia. Lung Cancer 125:253–257. https://doi.org/10.1016/j.lungcan.2018.10.008 CrossRefPubMedGoogle Scholar